

ASX Release

Anatara Funding Advance on R&D Refund

ADELAIDE, 1 May 2025: Anatara Lifesciences (ASX: ANR) ("**Anatara**" or "the **Company**"), a developer of evidence-based health products to address unmet needs, has entered into an agreement for an advance of \$400,000 (**Loan Facility** or **Advance**) on the Research & Development (R&D) Tax Incentive refund for FY2025 from a major shareholder group of the Company. This advance provides early access to approximately 80% of the Company's estimated R&D tax refund (**R&D Refund**) for activities conducted until the end of December 2024, being H1FY2025.

The Advance is to be provided under the terms of a loan agreement executed between Anatara and the major shareholder group. Anatara respects the request for anonymity from the counterparty in this loan facility and considers revealing the actual identity of the counterparty as irrelevant, as the significance is in the demonstration of support from a major shareholder group through very reasonable commercial terms for a short-term loan on a component of the expected FY2025 R&D refund. The Advance represents approximately 80% of the estimated R&D Refund for the first half of the current financial year only and incurs an interest rate of 11.0% per annum, calculated daily which can be repaid from the date that proceeds of the R&D Refund are received without penalty, or by no later than 4 August 2025. The funds are available on the 5 May 2025. There were no establishment fees or other costs. The Loan Facility otherwise contains terms and conditions customary for an agreement of this type.

Dr David Brookes, Executive Chair of Anatara, commented:

"The access to this component of the estimated R&D Tax Incentive refund is a sensible step given the timing of the Company's activities. Along with the additional R&D refund for the full FY that will be applied for in July 2025, the Company has funding to progress current activities including discussions on other opportunities and future directions, without other capital raising considerations. The internal analysis of the GaRP-IBS trial continues and will be formative in determining the commercial merit of the GaRP project. In addition, this runway of self-funding will take the Anti-Obesity Project beyond key early milestones in the Proof-of-Concept studies, which are expected to be a clear guide to the likelihood of success for that project. The Company appreciates the support of our shareholders and is working to restore value after the disappointment of the mixed results announced recently from the trial, which missed significance for the primary efficacy endpoint."

Anatara confirms that it does not consider the identity of the counterparty to be information that a reasonable person would expect to have a material effect on the price. Anatara confirms this announcement contains all material information relevant to assessing the impact of the contract and is not misleading by omission.



This ASX announcement has been approved and authorised for release by the Board of Anatara.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Jonathan Lindh
Company Secretary
+61 (0) 414 169 465
jlindh@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com

